During the financial year ended 31 March 2015, we invested S$30 billion and divested a record S$19 billion. We continued our strong pace of investments from the previous year, reflecting our constructive view of the global economy. In the latter part of the year, we capitalised on a significant liquidity-driven rally in some markets to step up our divestments.
In the consumer space, we completed a US$5.7 billion investment in A.S. Watson, a leading international health and beauty retailer, with over 11,600 stores operating 13 retail brands in 24 markets worldwide. With this investment, Temasek increased its exposure to the consumer retail sector, with a balanced focus on a growing Asia and a recovering Europe.
We continue to expand our financial services portfolio into non-banking sub-sectors, such as insurance, consumer finance, electronic market making and payments through investments in NN Group, Prudential plc, Synchrony Financial, Virtu Financial and Adyen. We also increased our holdings in Industrial and Commercial Bank of China.
In life sciences & agriculture, we increased our stake by about US$800 million in Gilead Sciences, a US-based biopharmaceutical company, which specialises in developing novel therapies for infectious diseases and cancer. We also invested in Ceva Santé Animale, a global animal health company, and COFCO International Limited, which holds a controlling stake in Nidera and Noble Agri, two international agriculture supply chain managers.
In terms of geography, Asia accounted for about half of our new investments during the year, followed by North America and Europe with a combined 43% share of our new investments.
In Asia, apart from the consumer investments in A.S. Watson and Olam, we invested actively in the telecommunications, media & technology sector. Our investments included Tencent, one of the top internet companies in China; Lazada, a leading South East Asia e-commerce platform; and Didi Kuaidi, a prominent Chinese transportation network company. We also invested in a number of consumer oriented companies in China, such as Yili Group and Kweichow Moutai.
We increased our exposure in India with investments in Global Health, the owner of the Medanta franchise of multi‑specialty, tertiary care hospitals; and in Intas Pharmaceuticals, a global generics company engaged in the development, manufacturing and marketing of pharmaceuticals formulations. We were also active in the technology sector in India with investments in Snapdeal, a leading e-commerce platform; Manthan, a data analytics company focused on the retail sector; and Cognizant Technology Solutions, a US-listed IT and business process outsourcing service provider with the majority of its operations in India.
In Europe, we made several investments in the UK real estate sector which included a combination of office and mixed-use development assets, such as MidCity Place and 22 Bishopsgate. Elsewhere in Europe, we invested in Deutsche Post DHL, an international logistics player; Origo Exploration, a North Sea oil exploration company; and Gaztransport & Technigaz, a global provider for liquefied natural gas (LNG) transport and storage. We increased our exposure to European financials as a play on European recovery, with investments in NN Group and Lloyds Banking Group.
In North America, apart from the life sciences & agriculture and financial services sectors, we made investments in the technology and energy sub-sectors. These included Internet Brands, a leader in software, marketplace and online media assets; Cheniere Energy, an energy company engaged in LNG related businesses; and a follow-on investment in Venari Resources, an upstream oil and gas exploration company focused on deep water Gulf of Mexico.
Key divestments included part of our stakes in China Construction Bank and Alibaba, where we continue to hold substantial positions. We exited our shareholdings in Mosaic, Qualcomm, Kunlun Energy and Medreich.